<DOC>
	<DOCNO>NCT01610037</DOCNO>
	<brief_summary>The study assess long-term safety fix combination product QVA149 versus placebo standard care treatment ( tiotropium ) Chronic Obstructive Pulmonary Disease ( COPD ) patient moderate severe airflow limitation .</brief_summary>
	<brief_title>Comparison Long-term Safety Combination Product QVA149A Against Placebo Standard Care Treatment Chronic Obstructive Pulmonary Disease Patients With Moderate Severe Airflow Limitation</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Tiotropium Bromide</mesh_term>
	<mesh_term>Glycopyrrolate</mesh_term>
	<criteria>Inclusion criterion : Male female adult age ≥40 year . Patients stable COPD accord GOLD strategy ( GOLD 2011 ) . Patients airflow limitation indicate postbronchodilator FEV1 ≥ 30 % &lt; 80 % predict normal , postbronchodilator . FEV1/FVC &lt; 0.70 . Current exsmokers smoke history least 10 pack year . Patients mMRC ≥ grade 2 Exclusion criterion : History long QT syndrome prolong QTc . Patients COPD exacerbation require treatment antibiotic and/or systemic corticosteroid and/or hospitalization 6 week prior Visit 1 . Patients Type I uncontrolled Type II diabetes . Patients history asthma concomitant pulmonary disease . Patients paroxysmal ( e.g . intermittent ) atrial fibrillation . Only patient persistent atrial fibrillation control rate control strategy least six month could eligible . Patients clinically significant renal , cardiovascular , neurological , endocrine , immunological , psychiatric , gastrointestinal , hepatic , hematological abnormality could interfere assessment safety .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>chronic obstructive pulmonary disease</keyword>
	<keyword>COPD</keyword>
	<keyword>QVA149</keyword>
	<keyword>QAB149</keyword>
	<keyword>NVA237</keyword>
	<keyword>Indacaterol maleate</keyword>
	<keyword>Glycopyronnium bromide</keyword>
</DOC>